The Role of Proteasome Inhibitors in Multiple Myeloma Bone Disease and Bone Metastasis: Effects on Osteoblasts and Osteocytes
Reads0
Chats0
TLDR
PIs have been recently proven to also be efficacious in blocking MM-induced osteocyte death providing new possible therapeutic use in the management of bone loss, and the conjugation of PIs with bisphosphonates showed good results in terms of bone anabolic activity.Abstract:
The alterations of bone remodeling are typical of multiple myeloma (MM) patients where the uncoupled and unbalanced bone remodeling caused the onset of osteolytic lesions. Moreover, bone metastasis occurs in the majority of patients with breast and prostate cancer. Skeletal-related events negatively impact on quality of life by increasing the vulnerability to fractures. Several bone-targeting treatments have been developed to control bone pain and pathological fractures, including bisphosphonates and Denosumab. Nevertheless, these agents act by inhibiting osteoclast activity but do not improve bone formation. Proteasome inhibitors (PIs) have shown bone anabolic effects and encouraging results in stimulating osteoblast differentiation and bone healing. Among these, the first-in-class bortezomib and the second-generation PIs, carfilzomib, and ixazomib regulate the bone remodeling process by controlling the degradation of several bone proteins. PIs have been recently proven to also be efficacious in blocking MM-induced osteocyte death providing new possible therapeutic use in the management of bone loss. PIs have significant side effects that limit their use as bone anabolic strategy. Multiple alternative approaches have been made. The conjugation of PIs with bisphosphonates, which can target them to bone, showed good results in terms of bone anabolic activity. However, the clinical implications of these effects require further investigations.read more
Citations
More filters
Journal ArticleDOI
Mechanisms, Diagnosis and Treatment of Bone Metastases
TL;DR: In this paper, the role of the bone marrow microenvironment in the attraction, homing, dormancy and outgrowth of metastatic tumor cells and the ensuing therapeutic implications is discussed.
Therapeutic targets in myeloma bone disease
TL;DR: In this paper, the authors discuss the mechanisms regulating the uncoupled bone remodelling in multiple myeloma (MM) and summarizes current advances in the treatment of MBD, including antiresorptive agents that are only partially effective due to their inability to repair the existing lesions.
Journal ArticleDOI
N-Heterocycle derivatives: An update on the biological activity in correlation with computational predictions
Sahar Saleh Alghamdi,Rasha Saad Suliman,Rawan Awadh Alshehri,Razan Suleiman Almahmoud,Renad Ibrahim Alhujirey +4 more
TL;DR: The selected N-heterocycle derivatives possess promising medicinal properties that could be utilized for future drug discovery, including oxazolone, oxazole, and oxadiazole.
References
More filters
Journal ArticleDOI
Destroy to Rebuild: The Connection Between Bone Tissue Remodeling and Matrix Metalloproteinases.
TL;DR: There remains a need to rethink the role played by proteases in bone physiology and pathology, with emphasis on the family of extracellular matrix metalloproteinases (MMPs).
Journal ArticleDOI
The ubiquitin-proteasome system and cellular proliferation and regulation in osteoblastic cells.
Elsa J. Brochmann Murray,Elsa J. Brochmann Murray,Gregory V. Bentley,Gregory V. Bentley,Mario S. Grisanti,Mario S. Grisanti,Samuel S. Murray,Samuel S. Murray +7 more
TL;DR: The ubiquitin-proteasome system is essential for osteoblast proliferation under control and PTH-treated conditions by enhancing ubiquitinylation of protein substrates and stimulating three major proteasome activities by a cAMP-dependent mechanism.
Journal ArticleDOI
Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma.
Bo Hu,Yu Chen,Saad Z. Usmani,Shiqiao Ye,Wei Qiang,Xenofon Papanikolaou,Christoph Heuck,Shmuel Yaccoby,Bart O. Williams,Frits van Rhee,Bart Barlogie,Joshua Epstein,Ya-Wei Qiang +12 more
TL;DR: It is demonstrated that carfilzomib significantly promoted mesenchymal stem cell differentiation into osteoblasts and induced osteoblast differentiation via Wnt-independent activation of the β-catenin/TCF pathway.
Journal ArticleDOI
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.
Maurizio Zangari,Monette Aujay,Fenghuang Zhan,Kristina L. Hetherington,Tamara Berno,Ravi Vij,Sundar Jagannath,David A. Siegel,A. Keith Stewart,Luhua Wang,Robert Z. Orlowski,Andrew R. Belch,Andrzej Jakubowiak,George Somlo,Suzanne Trudel,Nizar J. Bahlis,Sagar Lonial,Seema Singhal,Vishal Kukreti,Guido Tricot +19 more
TL;DR: This retrospective analysis of patients with relapsed or refractory Myeloma treated with single‐agent carfilzomib indicates that early elevation in ALP is associated with subsequent myeloma response.
Journal ArticleDOI
Adjuvant Drug-Assisted Bone Healing: Advances and Challenges in Drug Delivery Approaches.
Rebecca Rothe,Sandra Hauser,Christin Neuber,Markus Laube,Sabine Schulze,Stefan Rammelt,Jens Pietzsch,Jens Pietzsch +7 more
TL;DR: The focus is on the critical evaluation of recent preclinical studies investigating different carrier systems, dual- or co-delivery systems as well as triggered- or targeted delivery systems for release of a panoply of drugs.